دورية أكاديمية

The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients

التفاصيل البيبلوغرافية
العنوان: The Efficacy and Safety Associated with Switching from Concomitant Brimonidine and Ripasudil, or Brimonidine or Ripasudil Monotherapy to a Fixed Combination of Brimonidine and Ripasudil in Glaucoma Patients
المؤلفون: Hiromitsu Onoe, Kazuyuki Hirooka, Tetsuya Baba, Mikio Nagayama, Atsushi Hirota, Katsuyoshi Suzuki, Takeshi Sagara, Hideki Mochizuki, Yoshiaki Kiuchi
المصدر: Journal of Clinical Medicine, Vol 13, Iss 14, p 4158 (2024)
بيانات النشر: MDPI AG, 2024.
سنة النشر: 2024
المجموعة: LCC:Medicine
مصطلحات موضوعية: brimonidine, ripasudil, glaucoma, Medicine
الوصف: Objectives: The purpose of this study was to investigate switching from brimonidine and ripasudil, and brimonidine or ripasudil, to a fixed combination of brimonidine and ripasudil, and evaluate the associated efficacy and safety in glaucoma patients. Methods: Glaucoma patients undergoing treatment with at least brimonidine and ripasudil (n = 25) or treatment with at least brimonidine or ripasudil (n = 45) were evaluated in this retrospective study. After switching patients taking brimonidine and ripasudil, or brimonidine or ripasudil, to a ripasudil/brimonidine fixed-combination, ophthalmic suspension (RBFC), intra-ocular pressure (IOP), conjunctival hyperemia and superficial punctate keratopathy (SPK) were evaluated before and at 4, 12 and 24 weeks after switching to RBFC. Results: No significant differences in the IOPs were observed after switching from brimonidine and ripasudil to RBFC. However, a significant decrease was observed at 4, 12 and 24 weeks in the baseline IOP, from 17.0 ± 4.4 mmHg to 15.7 ± 3.2 mmHg (p < 0.01), 14.3 ± 3.4 mmHg (p < 0.01) and 14.4 ± 4.1 mmHg (p < 0.01), respectively, after switching from brimonidine or ripasudil to RBFC. No significant changes were noted for the SPK score or conjunctival hyperemia score at any of the visits after switching to RBFC. Conclusions: Throughout the 24-week evaluation period, the IOP was maintained after switching from brimonidine and ripasudil to RBFC. However, there was a significant decrease in the IOP after switching from brimonidine or ripasudil to RBFC. These results demonstrate that RBFC is safe for use in the treatment of glaucoma patients.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2077-0383
Relation: https://www.mdpi.com/2077-0383/13/14/4158; https://doaj.org/toc/2077-0383
DOI: 10.3390/jcm13144158
URL الوصول: https://doaj.org/article/036f315faf7d430abdfd0aed9a0c7664
رقم الأكسشن: edsdoj.036f315faf7d430abdfd0aed9a0c7664
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20770383
DOI:10.3390/jcm13144158